NBIX
Neurocrine Biosciences Inc
NASDAQ: NBIX · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$131.23
+2.43% today
Updated 2026-04-29
Market cap
$13.20B
P/E ratio
28.10
P/S ratio
4.61x
EPS (TTM)
$4.67
Dividend yield
—
52W range
$108 – $160
Volume
1.1M
Neurocrine Biosciences Inc (NBIX) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$131.23
12-Month target
$131.76
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1B | $1.5B | $1.9B | $2.4B | $2.9B | $3.4B | $4.1B | $4.9B | $5.9B |
| EPS | — | — | — | — | — | — | — | — | — |
CAGR applied: 20.00% (capped 20%) · P/E: 25.00x (capped 25x) · Margin: 16.70%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.